Clinical Research Directory
Browse clinical research sites, groups, and studies.
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
Sponsor: M.D. Anderson Cancer Center
Summary
The goal of this clinical research study is to offer lung cancer screenings to smokers who want to change their smoking behaviors. All eligible participants will receive smoking cessation counseling and may be offered at least one form of smoking cessation drug. Different forms of counseling (the delivery of counseling and access to counseling) will be compared. This is an investigational study. Participants on this study will not be prescribed smoking drugs directly by the study staff. However, participants in this study may or may not receive smoking cessation drugs, depending on what the provider thinks is in the participants best interest. All smoking cessation drugs being used are FDA approved and commercially available. It is investigational to compare the different forms of counseling participants receive. Up to 1260 participants will be enrolled in this study. All will take part at MD Anderson.
Official title: Optimizing Effectiveness of Smoking Cessation Intervention During Low Dose CT Screening for Lung Cancer
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
630
Start Date
2017-06-16
Completion Date
2026-06-01
Last Updated
2025-10-14
Healthy Volunteers
Yes
Conditions
Interventions
Questionnaires
Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
Low Dose Computed Tomography Scan
Participants have a CT scan of chest to look for signs of lung cancer.
Shared Decision Making + Video
Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
Cessation Counseling
Brief cessation counseling given by LDCT provider.
Quitline
Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
Pharmacotherapy Discussion
Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
Nicotine Patch
Nicotine patch dispensed. Dosing at physician's discretion.
Anti-Smoking Drug
Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
Tobacco Treatment Program
Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
Carbon Monoxide (CO) Level Test
Participant asked to blow air through a CO-measuring device.
Locations (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States